

13th July, 2018

BSE Limited
P J Towers,
Dalal Street,
Mumbai 400 001

Scrip Code: 532300

National Stock Exchange of India Limited Exchange Plaza Bandra-Kurla Complex, Bandra (E), Mumbai 400 051

NSE Symbol - WOCKPHARMA

Dear Sirs,

Sub: Compliance Report on Corporate Governance

In compliance with Regulation 27(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Compliance Report on Corporate Governance for the quarter ended 30th June, 2018.

Kindly acknowledge receipt of the same.

Thanking you,

For Wockhardt Limited

Narendra Singh Company Secretary

Encl: As above



Z (i

Corporate Governance Report

	o of Listed Entity : Wockhardt	Limited		-12.4						
	ter ending : 30th June, 2018 position of Board of Direct	ors		- 33						
Title (Mr. / Ms)	Name of the Director	PAN & DIN	DIN	Category (Chairperson/Executivel Non-Executive/Independent/ Nominee)	Date of Appointment In the current term	Tenure	No. of Directorship in Ilsted entitles Including this listed entity	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity	No. of post of Chairperson in AudiV Stakeholder Committee held in listed entities including this listed entity*	
Dr	Habil F Khorakiwala	PAN AA8PK4415C	00045608	Chairperson - Executive	01 03 2015	29,02,2020	Ī	0	0	
Dr	Huzaifa H Khorakıwala	ABLPK6715C	02191870	Executive	31.03.2014	30_03_2019	1	1	0	
Dr	Murtaza H Khorakiwala	AAZPK7040H	00102650	Managing Director - Executive	- 31,03,2014	30.03.2019	1	0	1	
Mr	Shekhar Dalla	AABPD6228L	00045591	Non-Executive - Independent	01,04,2014		3	2	72	
Dr	Sanjaya Baru	AAFPB4429H	05344208	Non-Executive - Independent	01,04 2014		2	3	- 0	
Mr	Aman Mehta	AAGPM5030J	00009364	Non-Executive - Independent	01,04 2014	Upto 31.03.2019	6	6		
Mr	D S Brar	AAGPB0665A	00068502	Non-Executive - Independent	01.04,2014		3	4	2	
Ms	Tasneem Mehta	AAAPZ1346C	05009664	Non-Executive - Independent	30 09 2014	Upto 29,09,2019	1	2		
Mr	Baldev Raj Arora	AAAPA5988R	00194168	Non-Executive - Independent	28,05,2015	Upto 27,05,2020	2	4	(
Mr	Vinesh Kumar Jalrath	AAYPJ0756C	00391684	Non-Executive - Independent	10 11,2016	Uplo 09.11.2021	5	7	1/2	
Ms.	Zahabiya H Khorakiwala	ANMPK3942N	00102689	Non-Executive - Non-Independent	30,10,2017	Upto the date of next AGM	2	1		
* A Dire	ector, wherever he is the Chain	person of the Committee.	is also a me							
	nposition of Committees									
2. Nomination & Remuneration Committee				Mr. Shekhar Datta Mr. Aman Mehta Mr. D S Brar Dr. Sanjaya Baru Ms. Tasneem Mehta Mr. Baldey Raj Arora Mr. Vinesh Kumar Jalrath Mr. Shekhar Datta Dr. Habit F, Khorakiwala Dr. Sanjaya Baru Mr. Aman Mehta Mr. Aman Mehta Mr. Aman Mehta Mr. Aman Mehta Mr. D S Brar				Executive/independent/Nominee) Chairperson - Non-Executive - Independent Executive - Independent Executive - Independent Non-Executive - Independent		
	eting of Board of Directors		Dr. Sanjaya Ms. Tasnee Mr. Baldev Mr. Vinash	Baru m Mehta Raj Arora Kumar Jairath	des		Non-Executive Non-Executive Non-Executive Non-Executive	- Independent - Independent - Independent - Independent - Independent	The market of March	
D	ate(s) of Meeting (if any) In th	e previous quarter	Date(s) of Meeting (if any) in the relevant quarter Maximum ga			p between any two consecutive (in number of days)				
	29.01.2018			04.05.2018			94 (excludi	ng date of meeting	is)	
L	neting of Committees** Date(s) of meeting of the nittee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s)	of meeting of the committee i quarter	in the previous	Maximum gap be			tings in number of days	
" Deta	04.05.2018 alls provided only for Audit Com	Yes		29.01.2018			94 (excludi	ng date of meeting	(5)	
	/									
y, Kei	lated Party Transactions Subject				Compl	iance status (Yes/N	lo/NA)			
Whelh	ner prior approval of audit cor	mmittee obtained	Yes							
Whether shareholder approval obtained for material RPT@			Yes							
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee			Yes							
@Tran	nsactions with Wockhardt Bio A ant to Regulation 27(2)(b) of SE	G. Related Party, are con EBI (LODR) Regulations,	nsidered ma 2015, the ma	terial and approval of sharehold alerial transactions with Wockha	ers have been obta ardt Bio AG for the	ained at the Annual quarter ended 30th	Seneral Meeting June, 2018 also	held on 15th Sept forms part of this f	ember, 2014, Further, Report	

- VI. Affirmations

 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes

 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

NOCKA

- 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 a. Audit Committee Yes
 b. Nomination & remuneration committee Yes
 c. Stakeholders relationship committee Yes
 d. Risk Management committee NA.
 The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes
 The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Yes
 This report and/or the report submitted in the previous quarter has been placed before Board of Directors. Any comments/observations/advice of Board of Directors may be mentioned here:
 The Report for quarter ended 31st March, 2018 was placed before the Board of Directors at their meeting held on 4th May, 2018.
 This Report for the quarter ended 31st March, 2018 shall be placed before the Board at the ensuing Board Meeting.

(mayele Narendra Singh Company Secretary and Compliance

13th July, 2018

WOCKHARDT LIMITED

DETAILS OF MATERIAL RELATED PARTY TRANSACTIONS FOR THE QUARTER ENDED 30TH JUNE, 2018

Name of Related Party	Name of transactions	Amount of transaction for the quarter ended 30th June, 2018 (Rs. in crores)					
Wockhardt Bio AG	Outlicensing Fees	2.94					
(Subsidiary	R&D Service	13.39					
Company)	Guarantee Fees Income	4.10					
	Management Fees	0.90					
	Sales of Finished Goods	69.40					
	Expenses Recovered	0.15					
	Expenses Reimbursed	0.13					
	Advances Received against Export of Goods & Services	140.63					
	Advances Adjusted against Export of Goods & Services	62.37					
	Total	294.01					
Note: The abo	Note: The above figures are unaudited subject to review of Au						

Narendra Singh

Company Secretary and Compliance Officer

13th July, 2018